Patient-specific dose finding in seamless phase I/II clinical trials

DOI10.1080/07474946.2022.2105361OpenAlexW4295812909MaRDI QIDQ5043686FDOQ5043686

Authors: M. Iftakhar Alam, Shantonu Islam Shanto 

Publication date: 6 October 2022

Published in: Sequential Analysis (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1080/07474946.2022.2105361

zbMATH Keywords

dose-finding studydose-response modelpatients' heterogeneityoptimum doseseamless phase I/II trial

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Sequential statistical design (62L05) Design of statistical experiments (62K99)

Cites Work

• Title not available (Why is that?)
• Dose-finding designs for HIV studies
• Patient‐Specific Dose Finding Based on Bivariate Outcomes and Covariates
• Dose-Response Models with Covariates
• Individualized dosing for multiple ordered groups of patients
• Biometric practicesimple benchmark for complex dose finding studies

Cited In (3)

• Making Efficient Use of Patients in Designing Phase III Trials Investigating Simultaneously a Set of Targeted Therapies with Different Targets
• Pharmacokinetically guided optimum adaptive dose selection in early phase clinical trials
• Patient‐Specific Dose Finding Based on Bivariate Outcomes and Covariates

This page was built for publication: Patient-specific dose finding in seamless phase I/II clinical trials

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q5043686)